| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/02/2005 | WO2005049631A1 Synthetic molecules having immune activity |
| 06/02/2005 | WO2005049627A1 Isoflavonoid prodrugs, compositions thereof and therapeutic methods involving same |
| 06/02/2005 | WO2005049623A1 PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| 06/02/2005 | WO2005049615A1 Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists |
| 06/02/2005 | WO2005049614A2 Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
| 06/02/2005 | WO2005049611A1 5-substituted imidazoles |
| 06/02/2005 | WO2005049609A1 Cycloalkyl derivatives of 3-hydroxy-4-pyridinones |
| 06/02/2005 | WO2005049608A1 Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
| 06/02/2005 | WO2005049601A1 Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| 06/02/2005 | WO2005049594A1 N-acylsulfonamide apoptosis promoters |
| 06/02/2005 | WO2005049593A2 N-acylsulfonamide apoptosis promoters |
| 06/02/2005 | WO2005049589A2 Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
| 06/02/2005 | WO2005049587A1 Process for preparation of biphenyl tetrazole |
| 06/02/2005 | WO2005049580A1 Monocyclic n-aryl hydantoin modulators of androgen receptor function |
| 06/02/2005 | WO2005049579A2 Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets |
| 06/02/2005 | WO2005049574A1 Androgen receptor modulators |
| 06/02/2005 | WO2005049564A1 Amide derivatives and methods of their use |
| 06/02/2005 | WO2005049561A2 Processes for preparing novel methylene blue derivative |
| 06/02/2005 | WO2005049559A2 Novel piperidine-substituted indoles- or hetero-derivatives thereof and their use as modulators of chemokine receptor (ccr-3) |
| 06/02/2005 | WO2005049558A1 Novel prostamides for the treatment of glaucoma and related diseases |
| 06/02/2005 | WO2005049211A2 Fiber rich fraction of trigonella foenum-graceum seeds and its use as a pharmaceutical excipient |
| 06/02/2005 | WO2005049142A2 Graduated estrogen contraceptive |
| 06/02/2005 | WO2005049090A2 Olanzapine containing transdermal drug delivery compositions |
| 06/02/2005 | WO2005049088A2 Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent |
| 06/02/2005 | WO2005049087A1 Remedy for chronic pelvic pain syndrome |
| 06/02/2005 | WO2005049084A2 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| 06/02/2005 | WO2005049080A1 Vaccine composition admixed with an alkylphosphatidylcholine |
| 06/02/2005 | WO2005049065A2 Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
| 06/02/2005 | WO2005049064A1 Drug therapy for celiac sprue |
| 06/02/2005 | WO2005049060A1 Composition and method for treatment of acne |
| 06/02/2005 | WO2005049053A1 Composition comprising a magnesium compound and/or a magnesium saltfor improving sexual dysfunction |
| 06/02/2005 | WO2005049050A1 Sialagogue and, containing the same, oral composition and food composition |
| 06/02/2005 | WO2005049049A1 Therapeutic peg solution concentrate |
| 06/02/2005 | WO2005049048A1 Fiber rich fraction of trigonella foenum-graecum and its use as a pharmaceutcal excipient |
| 06/02/2005 | WO2005049047A1 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis |
| 06/02/2005 | WO2005049046A1 Hypotensive drug and process for producing the same |
| 06/02/2005 | WO2005049045A1 Use of alpha-cyclodextrin in the preparation of medicaments for the treatment of human or animal diseases caused by parasites belonging to the genus cryptosporidium |
| 06/02/2005 | WO2005049044A1 Oligo-beta-(1, 3) -glucan and monoclonal antibodies against cancer |
| 06/02/2005 | WO2005049042A1 Combinations comprising ampa receptor antagonists for the treatment of tinnitus |
| 06/02/2005 | WO2005049041A1 Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders |
| 06/02/2005 | WO2005049040A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
| 06/02/2005 | WO2005049039A1 Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders |
| 06/02/2005 | WO2005049038A1 Strontium-based complexes, pharmaceutical compositions and dietetic products |
| 06/02/2005 | WO2005049037A1 Process for preparing phytosterol dispersions for application in beverages |
| 06/02/2005 | WO2005049036A1 USE OF 3-AZA-1-OXA-DIBENZO [e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS |
| 06/02/2005 | WO2005049035A1 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients |
| 06/02/2005 | WO2005049034A2 Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
| 06/02/2005 | WO2005049032A1 Inhibitors of the mutant form of kit |
| 06/02/2005 | WO2005049031A1 Combination |
| 06/02/2005 | WO2005049030A1 Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
| 06/02/2005 | WO2005049029A1 Combination therapy comprising the use of et-743 and doxorubicin for treating cancer |
| 06/02/2005 | WO2005049028A1 Use of cathepsin k inhibitors in severe bone loss diseases |
| 06/02/2005 | WO2005049027A2 Combinations useful for the treatment of neuronal disorders |
| 06/02/2005 | WO2005049026A1 Method and composition for treatment or prophylaxis of amyloidosis disorders |
| 06/02/2005 | WO2005049025A1 Method and composition for treatment of cutaneous lesions |
| 06/02/2005 | WO2005049024A2 Solid pharmaceutical preparation form |
| 06/02/2005 | WO2005049022A2 Use of dipeptidyl peptidase iv inhibitors |
| 06/02/2005 | WO2005049021A1 Materials and methods for inhibiting neointimal hyperplasia |
| 06/02/2005 | WO2005049020A1 Use of 1-thia-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 06/02/2005 | WO2005049018A1 Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
| 06/02/2005 | WO2005049017A1 Anti-inflammatory, regenerating and antimicrobial composition |
| 06/02/2005 | WO2005049016A1 USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| 06/02/2005 | WO2005049015A1 USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| 06/02/2005 | WO2005049014A1 Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders |
| 06/02/2005 | WO2005049013A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic. |
| 06/02/2005 | WO2005049012A2 Tryptophan for use in promoting and maintaining abstinence |
| 06/02/2005 | WO2005049011A1 USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| 06/02/2005 | WO2005049010A1 Use of 1-oxadibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 06/02/2005 | WO2005049009A1 Methods and agents for inhibiting dynamin-dependent endocytosis |
| 06/02/2005 | WO2005049008A1 Combinational radiotherapy and chemotherapy compositions and methods |
| 06/02/2005 | WO2005049007A1 Prevention and measures for viral infection |
| 06/02/2005 | WO2005049006A1 Remedy for diabetes |
| 06/02/2005 | WO2005049005A1 Inhibitor imaging agents |
| 06/02/2005 | WO2005049004A1 Plaster |
| 06/02/2005 | WO2005049003A1 Extended release dosage forms of bupropion hydrochloride |
| 06/02/2005 | WO2005049002A1 Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
| 06/02/2005 | WO2005049001A1 Anti-tumour terpene compounds |
| 06/02/2005 | WO2005049000A2 Treatment of phenylketonurias with bh4 |
| 06/02/2005 | WO2005048999A2 Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders |
| 06/02/2005 | WO2005048996A2 Modified release dosage forms of skeletal muscle relaxants |
| 06/02/2005 | WO2005048994A1 New formulation for retinoid-containing soft gelatin capsules |
| 06/02/2005 | WO2005048993A2 Minimization of drug oxidation in drug irradiated excipients formulations |
| 06/02/2005 | WO2005048992A1 Process for preparing clopidogrel compositions |
| 06/02/2005 | WO2005048991A1 Fosinopril composition |
| 06/02/2005 | WO2005048986A1 Stable liposome compositions comprising lipophilic amine containing pharmaceutical agents |
| 06/02/2005 | WO2005048982A2 Efficient introduction of an aerosol into a ventilator circuit |
| 06/02/2005 | WO2005048981A1 Controlled release of topirimate in liquid dosage forms |
| 06/02/2005 | WO2005048957A2 Novel insertion sites in pox vectors |
| 06/02/2005 | WO2005048956A2 Estradiol-related compounds and methods of use as anti-tumor agents |
| 06/02/2005 | WO2005048955A2 Preloading with macular pigment to improve photodynamic treament of retinal vascular disorders |
| 06/02/2005 | WO2005048953A2 Amide derivatives as kinase modulators |
| 06/02/2005 | WO2005048952A2 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 06/02/2005 | WO2005048948A2 Urea derivatives as kinase modulators |
| 06/02/2005 | WO2005048942A2 Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| 06/02/2005 | WO2005048932A2 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
| 06/02/2005 | WO2005048930A2 Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| 06/02/2005 | WO2005048929A2 Plant-derived protein extract compositions and methods |
| 06/02/2005 | WO2005048928A2 Methods for treating viral infection |
| 06/02/2005 | WO2005048927A2 Methods and reagents for the treatment of inflammatory disorders |
| 06/02/2005 | WO2005048926A2 Methods for treating pain |